Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, today publishes its review of 2018 - a record year with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact Fund and significant expansion of the team
Copenhagen, Denmark, 4 January 2019 – Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, today publishes its review of 2018 - a record year with six new investments, two portfolio companies closed major financing rounds, the launch of the REPAIR Impact Fund and significant expansion of the team. For more information, please see the Novo Seeds January 2019 Newsletter.
Søren Møller, Managing Partner at Novo Seeds, commented: “In the Nordics and the rest of Europe we identify breakthrough scientific discoveries that have the potential to deliver innovative therapies and better treatment for patients. As one of the largest company creator teams in Europe, our mission is to create and build life sciences companies developing novel treatments that can make a significant difference to patients’ lives.
“The successes in 2018 reflect the excellent work done by our team and the achievements across our portfolio of companies. It is testament to our commitment to life sciences that – over the last 10 years – the vast majority of Danish biotechs with International VC investors have been incubated and built by Novo Seeds.”
In 2018, the Novo Seeds team reviewed approximately 400 opportunities and made six investments ranging in size from €250,000 to €12.5 million. Its investment strategy enables the team to build life sciences companies and attract financing rounds needed to bring them to real inflection points. From a financial perspective the team can invest up to €20 million per financing round supporting portfolio companies to an exit.
Read the full newsletter here.
ENDS
Enquiries
For more information on Novo Seeds, please contact:
Novo Holdings
Søren Møller, Managing Partner
+45 3527 6500
Optimum Strategic Communications
Hollie Vile, Mary Clark
+44 (0) 787 687 2224
About Novo Holdings
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and manages the Foundation’s assets.
In addition to being the major shareholder in the Novo Group companies, Novo Holdings provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within life science and manages a broad portfolio of financial assets.
It is the vision of Novo Holdings to be recognized as a world-leading life science investor with a focus on creating long-term value. Read more atwww.novoholdings.dk.
